The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N-(4-(6,7-dimethoxy-2-methylquinolin-3-yloxy)phenyl)-3,5-bis(trifluoromethyl)benzamide ID: ALA4792731
PubChem CID: 155812925
Max Phase: Preclinical
Molecular Formula: C27H20F6N2O4
Molecular Weight: 550.46
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: COc1cc2cc(Oc3ccc(NC(=O)c4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c(C)nc2cc1OC
Standard InChI: InChI=1S/C27H20F6N2O4/c1-14-22(10-15-11-23(37-2)24(38-3)13-21(15)34-14)39-20-6-4-19(5-7-20)35-25(36)16-8-17(26(28,29)30)12-18(9-16)27(31,32)33/h4-13H,1-3H3,(H,35,36)
Standard InChI Key: JHLFWBZMEWIVII-UHFFFAOYSA-N
Molfile:
RDKit 2D
39 42 0 0 0 0 0 0 0 0999 V2000
2.1613 -8.8466 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.1601 -9.6740 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8750 -10.0870 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8732 -8.4338 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5886 -8.8430 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.5894 -9.6699 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3047 -10.0808 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.0199 -9.6661 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.0151 -8.8360 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.2992 -8.4287 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4485 -8.4372 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.4459 -10.0843 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.4466 -7.6121 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4441 -10.9093 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7287 -8.4209 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.7360 -10.0759 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4446 -8.8310 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4423 -9.6562 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.1573 -10.0662 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.8714 -9.6512 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.8661 -8.8219 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.1504 -8.4156 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.5888 -10.0643 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
9.3028 -9.6510 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.0178 -10.0627 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.3019 -8.8259 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
10.0157 -10.8854 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.7299 -11.2971 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.4450 -10.8837 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.4413 -10.0544 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.7266 -9.6464 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.1515 -9.6405 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.8533 -10.1077 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
11.7900 -8.8685 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
12.8665 -9.3296 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
10.7305 -12.1218 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.9736 -12.4930 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
11.5797 -12.1982 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
10.6393 -12.8961 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 8 2 0
8 9 1 0
9 10 2 0
10 5 1 0
1 11 1 0
2 12 1 0
11 13 1 0
12 14 1 0
9 15 1 0
8 16 1 0
15 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
20 21 1 0
21 22 2 0
22 17 1 0
20 23 1 0
23 24 1 0
24 25 1 0
24 26 2 0
25 27 2 0
27 28 1 0
28 29 2 0
29 30 1 0
30 31 2 0
31 25 1 0
32 33 1 0
32 34 1 0
32 35 1 0
30 32 1 0
36 37 1 0
36 38 1 0
36 39 1 0
28 36 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 550.46Molecular Weight (Monoisotopic): 550.1327AlogP: 7.64#Rotatable Bonds: 6Polar Surface Area: 69.68Molecular Species: NEUTRALHBA: 5HBD: 1#RO5 Violations: 2HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): 2CX Acidic pKa: ┄CX Basic pKa: 5.19CX LogP: 6.29CX LogD: 6.29Aromatic Rings: 4Heavy Atoms: 39QED Weighted: 0.25Np Likeness Score: -1.00
References 1. El-Damasy AK,Haque MM,Park JW,Shin SC,Lee JS,EunKyeong Kim E,Keum G. (2020) 2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAF/C-RAF kinase inhibitory effects: Design, synthesis, in vitro cell-based and oncogenic kinase assessments., 208 [PMID:32942186 ] [10.1016/j.ejmech.2020.112756 ]